Claims

1. At least one chemical entity chosen from compounds of Formula (I) :



wherein:
A represents hydroxy;

R^1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, each of which may be optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, -CF_3, -OCF_3, $NR^ESO_2R^D$, phenyl and heterocyclyl, wherein the -C_{1-6}alkyl substituent itself may be optionally substituted by one or more substituents selected from -C_{5-9}cycloalkyl, halo, -NR^BR^C, -$C(O)NR^BR^C$, -$NR^EC(O)R^D$, -SR^A, -SO_2R^D, OR^A, oxo, phenyl, heteroaryl or heterocyclyl; or R^1 represents -C_{1-6}alkyl or -C_{5-9}cycloalkyl;

R^2 represents phenyl substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^2 represents -$(CH_2)_nC_{5-7}$cycloalkyl optionally substituted on the cycloalkyl by one or more substitutents selected from -C_{1-6}alkyl, =$CH(CH_2)_tH$, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, and heterocyclyl, or wherein two substituents may together form a -C_{1-2}alkylene bridge substituent;

t represents 0, 1, 2, 3 or 4;

n represents 0 or 1;

R^3 represents heterocyclyl or heteroaryl; or phenyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^3 represents -C_{1-6}alkyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, phenyl, heteroaryl and heterocyclyl;

R^4 represents hydrogen;

R^A represents hydrogen, -C_{1-6}alkyl, arylalkyl, heteroarylalkyl, aryl, heterocyclyl or heteroaryl;

R^B and R^C independently represent hydrogen, -C_{1-6}alkyl, aryl, heterocyclyl or heteroaryl; or R^B and R^C together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

R^D is selected from the group consisting of -C_{1-6}alkyl, aryl, heterocyclyl, heteroaryl, arylalkyl, and heteroarylalkyl;

R^E represents hydrogen or -C_{1-6}alkyl;

R^F and R^G are independently selected from the group consisting of hydrogen, -C_{1-6}alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R^F and R^G together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

and salts, solvates and esters thereof.

2. At least one chemical entity as claimed in claim 1 chosen compounds of Formula (I) selected from the group consisting of:
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-phenyl-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(4-methylphenyl)-1H-pyrazole-4-carboxylic acid;
1-(1-Cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Chloro-3-methylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Fluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(6-Indolyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Hydroxyphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
1-[4-(Acetylamino)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Biphenylyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-[4-(Dimethylamino)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(methyloxy)phenyl]-1H-pyrazole-4-carboxylic acid;
1-(4-Acetylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(trifluoromethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;
1-(4-Cyanophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-{4-[(Dimethylamino)carbonyl]phenyl}-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3-thienyl)-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
1-(3,5-Dimethylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Chloro-5-fluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[3,5-Bis(trifluoromethyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(1,3-Benzodioxol-5-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(2,3-Dihydro-1-benzofuran-5-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3,4,5-trifluorophenyl)-1H-pyrazole-4-carboxylic acid;
1-(4-Chlorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[3-(methyloxy)phenyl]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxylic acid;
1-(2-Fluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Hydroxyphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3-methylphenyl)-1H-pyrazole-4-carboxylic acid;

1-(3-Fluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Aminophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Chlorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{3-[(trifluoromethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;
1-(4-Chloro-3-fluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Amino-4-methylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Fluoro-4-methylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3,4-Difluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[(E)-1-Hexen-1-yl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[(E)-2-Cyclohexylethenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[(E)-4-methyl-1-penten-1-yl]-1H-pyrazole-4-carboxylic acid;
1-[(E)-2-(4-Fluorophenyl)ethenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Ethenylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-(Hydroxymethyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Ethylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(1-methylethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
1-(5-Acetyl-2-thienyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(5-Chloro-2-thienyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(5-methyl-2-thienyl)-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(5-phenyl-2-thienyl)-1H-pyrazole-4-carboxylic acid;
1-((4-Methyl)cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;

1-(6-Benzofuranyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(Cyclohepten-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;
1-((4-Methyl)cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-(methylsulfonyl)-4-piperidinyl]amino]-1H-pyrazole-4-carboxylic acid;
1-((4,4-Dimethyl)cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Chloro-4-benzyloxyphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Benzyloxy-cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1)-1H-pyrazole-4-carboxylic acid;
1-(4,4-Dimethyl)cyclohexen-1-yl)-3-{[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(E)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(Z)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(Z)-2-(3-pyrazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(E)-2-(3-pyrazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(E)-2-(tetrahydro-2H-pyran-4-yl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(E)-2-(4-thiazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(Z)-2-(4-thiazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
1-((E)-2-*tert*-Butyl-ethenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-((E)-2-Phenyl-ethenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4-Methyl-1-cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(3-Cyanophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-{(1-Methylethyl)[(4-methylidenecyclohexyl)carbonyl]amino}-1-phenyl-1*H*-pyrazole-4-carboxylic acid;
1-(4-Trifluoromethyl-cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenyloxy)methyl] phenyl}-1*H*-pyrazole-4-carboxylic acid;

1-[4-(Phenylsulfonylmethyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-(Phenylthiomethyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-(Phenoxy)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-{(1,3-Thiazol-4-ylmethyl)oxy}phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E]-Phenylethenyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-[Z]-Phenylethenyl))phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E,Z]-(1,3-Thiazol-2-yl)ethenyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E]-Phenyl-2-methylethenyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-[E]-(Pyridin-4-yl)ethenyl))phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E]-(1,3-Thiazol-4-yl)ethenyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E]-(Furan-2-yl)ethenyl))phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-[4-([E]-(2-Methyl-1,3-thiazol-4-yl)ethenyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[(Cyclohexylacetyl)(1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{(1-Methylethyl)[(4-methylphenyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(4-Bromo-2-chlorophenyl)carbonyl](1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](phenyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{[2-(Dimethylamino)-2-oxoethyl][(*trans*-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-([(*trans*-4-Methylcyclohexyl)carbonyl]{1-[(methyloxy)carbonyl]-4-piperidinyl}amino)-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{[(*trans*-4-Methylcyclohexyl)carbonyl][1-(methylsulfonyl)-4-piperidinyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methyl-4-piperidinyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{{1-[(Ethylamino)carbonyl]-4-piperidinyl}[(*trans*-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](2-pyrazinylmethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;

rel-3-[{[(1S,2R,4S)-2-Hydroxy-4-methylcyclohexyl]carbonyl}(1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(3-methoxyphenylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenylmethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;
1-(1H-Indol-5-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(E/Z)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(2-phenylethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[2-phenylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-[(1,3-thiazol-4-yl)-ethyl]phenyl]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(1,3-thiazol-4-yl)-ethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
1-Cyclohexyl-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[1-(methylsulfonyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](phenylmethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{Cyclopentyl[(*trans*-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-{(1-Acetyl-4-piperidinyl)[(*trans*-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](4-piperidinyl)amino]-1-phenyl-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(E)-2-cyclohexylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
1-[4-(2-Cyclohexylethyl)phenyl]-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[2-pyridinylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[2-pyridinylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;

3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[1,3-thiazol-2-ylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[2-(1*H*-pyrazol-3-yl)ethyl]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenylamino)carbonyl]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(3-methylphenylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-([(*trans*-4-Methylcyclohexyl)carbonyl]{1-[(*tert*-butyloxy)carbonyl]-4-piperidinyl}amino)-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(4-fluorophenylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(cyclohexylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
1-(4-{[(4-Fluorophenyl)amino]carbonyl}phenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{3-[(chlorophenylcarbonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
3-[[(*trans*-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenylsulfonyl)amino]phenyl}-1*H*-pyrazole-4-carboxylic acid;
1-(4-Methyl-1-cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1*H*-pyrazole-4-carboxylic acid;
1-(4,4-Dimethyl-1-cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](tetrahydro-3-furanyl)amino]-1*H*-pyrazole-4-carboxylic acid
and salts, solvates and esters, and individual enantiomers thereof where appropriate.

3. A method of treating or preventing viral infection which comprises administering to a subject in need thereof, an effective amount of at least one chemical entity chosen from compounds of Formula (I)



wherein:

A represents hydroxy;

R^1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, each of which may be optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, -CF_3, -OCF_3, $NR^ESO_2R^D$, phenyl and heterocyclyl, wherein the -C_{1-6}alkyl substituent itself may be optionally substituted by one or more substituents selected from -C_{5-9}cycloalkyl, halo, -NR^BR^C, -$C(O)NR^BR^C$, -$NR^EC(O)R^D$, -SR^A, -SO_2R^D, OR^A, oxo, phenyl, heteroaryl or heterocyclyl; or R^1 represents -C_{1-6}alkyl or -C_{5-9}cycloalkyl;

R^2 represents phenyl substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^2 represents -$(CH_2)_nC_{5-7}$cycloalkyl optionally substituted on the cycloalkyl by one or more substitutents selected from -C_{1-6}alkyl, $=CH(CH_2)_tH$, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, and heterocyclyl, or wherein two substituents may together form a -C_{1-2}alkylene bridge substituent;

t represents 0, 1, 2, 3 or 4;

n represents 0 or 1;

R^3 represents heterocyclyl or heteroaryl; or phenyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^3 represents -C_{1-6}alkyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, phenyl, heteroaryl and heterocyclyl;

R^4 represents hydrogen;

R^A represents hydrogen, -C_{1-6}alkyl, arylalkyl, heteroarylalkyl, aryl, heterocyclyl or heteroaryl;

R^B and R^C independently represent hydrogen, -C_{1-6}alkyl, aryl, heterocyclyl or heteroaryl; or R^B and R^C together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

R^D is selected from the group consisting of -C_{1-6}alkyl, aryl, heterocyclyl, heteroaryl, arylalkyl, and heteroarylalkyl;

R^E represents hydrogen or -C_{1-6}alkyl;

R^F and R^G are independently selected from the group consisting of hydrogen, -C_{1-6}alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R^F and R^G together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;
and salts, solvates and esters thereof.

4. A method as claimed in claim 3 which involves inhibiting HCV replication.

5. A method as claimed in claim 3 in which the chemical entity is administered in an oral dosage form.

6. At least one chemical entity chosen from compounds of Formula (I)



wherein:
A represents hydroxy;

R^1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, each of which may be optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, -CF_3, -OCF_3, $NR^ESO_2R^D$, phenyl and heterocyclyl, wherein the -C_{1-6}alkyl substituent itself may be optionally substituted by one or more substituents selected from -C_{5-9}cycloalkyl, halo, -NR^BR^C, -$C(O)NR^BR^C$, -$NR^EC(O)R^D$, -SR^A, -SO_2R^D, OR^A, oxo, phenyl, heteroaryl or heterocyclyl; or R^1 represents -C_{1-6}alkyl or -C_{5-9}cycloalkyl;

R^2 represents phenyl substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^2 represents -$(CH_2)_nC_{5-7}$cycloalkyl optionally substituted on the cycloalkyl by one or more substitutents selected from -C_{1-6}alkyl, =$CH(CH_2)_tH$, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, and heterocyclyl, or wherein two substituents may together form a -C_{1-2}alkylene bridge substituent;

t represents 0, 1, 2, 3 or 4;

n represents 0 or 1;

R^3 represents heterocyclyl or heteroaryl; or phenyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, halo, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, nitro, cyano, and heterocyclyl; or R^3 represents -C_{1-6}alkyl optionally substituted by one or more substituents selected from -C_{1-6}alkyl, -OR^A, -SR^A, -$C(O)NR^BR^C$, -$C(O)R^D$, -CO_2H, -CO_2R^D, -NR^BR^C, -$NR^EC(O)R^D$, -$NR^ECO_2R^D$, -$NR^EC(O)NR^FR^G$, -$SO_2NR^FR^G$, -SO_2R^D, fluoro, nitro, cyano, oxo, phenyl, heteroaryl and heterocyclyl;

R^4 represents hydrogen;

R^A represents hydrogen, -C_{1-6}alkyl, arylalkyl, heteroarylalkyl, aryl, heterocyclyl or heteroaryl;

R^B and R^C independently represent hydrogen, -C_{1-6}alkyl, aryl, heterocyclyl or heteroaryl; or R^B and R^C together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

R^D is selected from the group consisting of -C_{1-6}alkyl, aryl, heterocyclyl, heteroaryl, arylalkyl, and heteroarylalkyl;

R^E represents hydrogen or -C_{1-6}alkyl;

R^F and R^G are independently selected from the group consisting of hydrogen, -C_{1-6}alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R^F and R^G together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

and salts, solvates and esters thereof.
for use in medical therapy.

7. A compound as claimed in claim 6 wherein the medical therapy is the treatment of viral infection.

8. A compound as claimed in claim 7 wherein the viral infection is HCV.

9. A pharmaceutical formulation comprising at least one chemical entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts, solvates and esters thereof as defined in claim 1 in conjunction with at least one pharmaceutically acceptable diluent or carrier.

10. A process for the preparation of a compound of Formula (I) as defined in claim 1, comprising treatment of a compound of Formula (II)



(II)

in which A is an alkoxy, benzyloxy or silyloxy group and R^1, R^2, R^3 and R^4 are as defined above for Formula (I) with a base.

11. A process as claimed in claim 10 in which A is ethoxy.

12. Use of at least one chemical entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts, solvates and esters thereof as claimed in claim 1, in the manufacture of a medicament for the treatment and/or prophylaxis of viral infection.

13. Use as claimed in claim 12 wherein the viral infection is HCV.